Haemacure Starts Construction on New State-of-the-Art Biologics Facility - Produces Fibrin Sealant Samples - Hires Senior Scientists - Insiders Purchase Shares



    HAE: TSX

    MONTREAL, Dec. 13 /CNW Telbec/ - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company, announces the start of
construction of its manufacturing facility, the production of laboratory
samples of fibrin sealant, the hiring of two senior scientists and shares
purchases by insiders.

    Manufacturing Facility

    Construction is underway at the facility to prepare for the installation
of the clean room. Haemacure is on plan to have an operational facility by
mid-2008. Construction of a state-of-the-art facility incorporating the latest
proven manufacturing components is a major milestone that will require
significantly lower capital investment than originally planned. The facility
will also allow lower operating costs and higher final product safety
standards.

    Fibrin Sealant Samples

    Haemacure has produced in its laboratory samples of its proprietary
fibrin sealant for delivery to potential partners for evaluation as a part of
a collaboration program. This will enable these partners to evaluate the
product in their labs and see how it can enhance the performance of their own
products, in wound management, regenerative medicine, drug delivery and
combination with biomaterials applications.

    Scientists

    Haemacure is pleased to welcome Dr. Trung Bui-Khac, Ph.D. in chemistry,
and Mrs. Véronique Boulanger, B. Sc. in biochemistry and M. Sc., as new
employees of the Company. Dr. Bui-Khac is a former Vice-President of Haemacure
and the inventor of three of the four inventions making up Haemacure's
patented fibrinogen and thrombin extraction technology. Dr. Bui-Khac holds the
position of Director of Technical Development. Mrs. Boulanger possesses
relevant experience in protein biochemistry and holds the position of Senior
Scientist. Both Dr. Bui-Khac and Mrs. Boulanger work at Haemacure's Montreal
laboratory, where they produced samples of Haemacure's fibrin sealant.

    Shares Purchases

    Haemacure also reports that certain of its directors and officers have
purchased directly and indirectly in excess of 1 million shares of the
Corporation on the secondary market at prices ranging from $0.12 to $0.155 per
share. The purchases were made between October 26 and November 30, 2007 in
accordance with regulatory requirements and filed with the System for
Electronic Disclosure for Insiders (SEDI), where further details on individual
purchases may be accessed.

    "I am very excited with the rapid progress we have made since announcing
our First-Patient-In-The-Clinic strategy for fibrin sealant on October 24,
2007. I am also pleased with this strengthening of our scientific and
technical team and the product samples they have produced", said Joseph Galli,
Chairman and CEO of Haemacure. "Haemacure is well on its way to delivering on
the turnaround plan initiated on February 1, 2007 and will be positioned as
the only independent, next generation, human fibrin sealant global supplier,
concluded Mr. Galli.

    About Haemacure

    Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma protein products for commercialization. Haemacure's
research and development effort is driven by its proprietary plasma protein
extraction technology to develop next-generation products, including surgical
hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin
sealant to enter pivotal Phase II/Phase III clinical trials. Haemacure's
second product candidate is thrombin, a component of its fibrin sealant.
Follow-on development will focus on surgical hemostats, adhesion prevention,
wound healing, regenerative medecine, drug delivery in select therapeutic
areas and combination with biomaterials. Haemacure has discovered additional
specialty proteins in one if its two plasma fractions and seeks to advance
these specialty proteins through partnerships with pharmaceutical and
biotechnology companies. Haemacure operates offices in Sarasota, Florida
through a wholly-owned subsidiary. The Corporation is traded under stock
symbol HAE on the TSX.

    Forward-looking Statements

    Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.




For further information:

For further information: Haemacure Corporation: Joseph Galli, Chairman
and CEO Investor, (514) 990-7074, jgalli@haemacure.ca; Gilles Lemieux,
Relations, (514) 282-3350, ext. 22, glemieux@haemacure.ca; www.haemacure.com

Organization Profile

HAEMACURE CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890